Evidence map›Paper›PMID 41892824›Full record

ReviewMedical sciences (Basel, Switzerland)2026

Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection.

Ajibola Anifowose, Marco Tagliafierro, Ghadeer Mahdi, Saada Hussein, Massimo Baudo, Tulio Caldonazo, Aleksander Dokollari, Kaveh Hosseini, William D T Kent, Ali Fatehi Hassanabad

Abstract readReview
In one paragraph

Review in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ajibola AnifowoseFaculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2G5, Canada.ORCID 0009-0001-3487-4246
Marco TagliafierroSection of Cardiac Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0009-0006-7585-7166
Ghadeer MahdiDivision of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.
Saada HusseinDivision of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.
Massimo BaudoDepartment of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA 19096, USA.ORCID 0000-0003-3754-6704
Tulio CaldonazoDepartment of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, 07747 Jena, Germany.ORCID 0000-0001-5697-2659
Aleksander DokollariSection of Cardiac Surgery, St. Boniface Hospital, University of Manitoba, Winnipeg, MB R2H 2A6, Canada.ORCID 0000-0002-9928-3316
Kaveh HosseiniDepartment of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, 2100 Copenhagen, Denmark.
William D T KentDivision of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0002-3808-0777
Ali Fatehi HassanabadSection of Cardiac Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder characterized by a dynamic left ventricular outflow tract (LVOT) obstruction and an increased risk of sudden cardiac death. For patients with symptoms refractory to medical management, or intolerant to the new selective myosin inhibitor, septal reduction therapy (SRT) with surgical septal myectomy (SM) is indicated. This narrative review provides a contemporary assessment of septal myectomy, integrating its historical development, technical advancements, and comparative long-term outcomes. SM is established as the current reference standard, offering extensive anatomical relief and favorable long-term survival in clinical registries. It consistently achieves residual LVOT gradients <10 mmHg and enables correction of complex accessory mitral pathologies, leading to significant reverse ventricular and atrial remodeling. In contrast, ASA, a less invasive alternative for high-risk surgical candidates, is limited by incomplete tissue necrosis. This results in higher residual gradients (15-20 mmHg), increased rates of re-intervention (10-20%) and incidence of permanent pacemaker implantation (10-17.4%) and an associated greater risk of long-term all-cause mortality (>5 years). The disparity in long-term survival and the risk associated with sequential septal reduction procedures underscore the critical need for precise patient selection guided by institutional expertise. Furthermore, advancements like virtual surgical myectomy and transapical beating-heart septal myectomy are expanding the scope of intervention. This review synthesizes comparative contemporary data on HOCM management, highlighting the need for prospective, multicenter studies to address enduring knowledge gaps concerning equitable access, genotype integration, and long-term comparative effectiveness as current evidence remains dominated by retrospective studies.

Indexed as

Cardiomyopathy, HypertrophicSeptal MyectomyHeart SeptumHumansPatient SelectionTreatment OutcomeVentricular Outflow Obstruction, Leftclinical outcomeshypertrophic obstructive cardiomyopathymedical therapyseptal ablation therapyseptal myectomy

Identifiers

PMID41892824
PMCPMC13027486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.